DEPARTMENT OF HEALTH SERVICES

Division of Mental Health and Substance Abuse Services F-24277 (12/2010)

STATE OF WISCONSIN 42 CFR483.420(a)(2) DHS 134.31(3)(o) DHS 94.03 & 94.09

s.51.61(1)(g) & (h)

INFORMED CONSENT FOR MEDICATION

Dosage and / or Side Effect information last revised on 12/17/2010

Completion of this form is voluntary. If	_	olde Ellect Illionii				ss in an emergency
This consent is maintained in the client's re				accessible to	authorized users.	
Name – Patient / Client (Last, First, MI)			ID Num	ber	Living Unit	Birthdate
Name – Individual Preparing This Form Name – Staff		Name – Staff Cor	Contact		Name / Telephone Nur	mber – Institution
MEDICATION CATEGORY		MEDICATION			ECOMMENDED TAL DOSAGE RANGE	ANTICIPATED DOSAGE RANGE
Central Nervous System Stimulant	Adderall; Adderall XR (Mixed Salts of A Single Entity Amphetamine)		ity	2.5mg - 30mg		
The anticipated dosage range is to be without your informed and written cons Recommended daily total dosage rang This medication will be administered	sent.	•	<u>nysician's</u>		-	
Reason for Use of Psychotropic Include DSM IV diagnosis or the di			ed (note	if this is 'Off I	Label' Use)	
2. Alternative mode(s) of treatment Note: Some of these would be app -Environment and / or staff change -Positive redirection and staff intera -Individual and / or group therapy Other Alternatives:	olicable only in s	an inpatient enviror	nment. -Reha -Trea	abilitation treatr ment program	ments / therapy (OT, PT, s and approaches (habili ervention techniques	
Probable consequences of NO	OT receiving t	he proposed med	ication a	'e		
Impairment of		Family Relationship			☐ -Social Functioning	
Possible increase in symptoms lead -Use of seclusion or restraints -Limits on access to possessions -Limits on personal freedoms -Limit participation in treatment and Other consequences		ial	-Inter		and leisure activities enforcement authorities or others	
Note: These consequences ma						also possible that in
unusual situations, little or no ac	dverse conseq	uences may occur i	the med	ications are no	t administered.	See Page 2

Client Initial

Date ___

Medication: Adderall:

Adderall XR - (Mixed Salts of A Single Entity Amphetamine)

4. Possible side effects, warnings and cautions associated with this medication are listed below. This is not an all inclusive list but is representative of items of potential clinical significance to you. For more information on this medication, you may consult further with your physician or refer to a standard text such as the PDR or the United States Pharmacopoeia Dispensing Information (USPDI). As part of monitoring some of these potential side effects, your physician may order laboratory or other tests. The treatment team will closely monitor individuals who are unable to readily communicate side effects, in order to enhance care and treatment.

Continued – Possible side effects, warnings and cautions associated with this medication.

Check with your doctor immediately if any of the following more common side effects occur: Anxiety; crying; depersonalization; dry mouth; dysphoria; euphoria; fast, pounding, or irregular heartbeat or pulse; hyperventilation; irritability; mental depression; nervousness; paranoia; quick to react or overreact emotionally; rapidly changing moods; restlessness; shaking; shortness of breath; trouble sleeping.

Other common side effects may include: False sense of well-being; irritability; nervousness; restlessness; trouble in sleeping. After these stimulant effects have worn off, drowsiness, trembling, unusual tiredness or weakness, or mental depression may occur.

Check with your doctor immediately if any of the following less common side effects occur: Chills; cold flu-like symptoms; cough or hoarseness; difficult or labored breathing; lower back or side pain; painful or difficult urination; tightness in chest; wheezing. Other Less common side effects include: Accidental injury; bladder pain; bloody or cloudy urine; blurred vision; changes in sexual desire or decreased sexual ability; constipation; cramps; diarrhea; difficult, burning, or painful urination; difficulty in speaking; dizziness or lightneadedness; dryness of mouth or unpleasant taste; fast or pounding heartbeat; frequent urge to urinate; headache; heavy bleeding with menstrual period; inability to have or keep an erection; increased sensitivity of skin to sunlight; increased sweating; itching, redness or other discoloration of skin; loss of appetite; lower back or side pain; nausea or vomiting; pain; severe sunburn; sleepiness or unusual drowsiness; tooth disorder; twitching; weight loss.

Check with your doctor immediately if any of the following rare side effects occur: Chest pain; fever, unusually high; skin rash or hives; uncontrolled movements of head, neck, arms, and legs.

After the stimulant effects have worn off, drowsiness, trembling, unusual tiredness or weakness, or mental depression may occur. Also, with long-term use or high doses you may experience difficulty in breathing; dizziness or feeling faint; increased blood pressure; mood or mental changes; pounding heartbeat; unusual tiredness or weakness.

BLACK BOX WARNING

Amphetamines have a high potential for abuse. Particular attention should be paid to the possibility of subjects obtaining amphetamines for non-therapeutic use or distribution to others, and the drugs should be prescribed or dispensed sparingly.

Drug dependence--Administration of amphetamines for prolonged periods of time may lead to drug dependence and must be avoided.

Serious Adverse Events—Misuse of amphetamines may cause sudden death and serious cardiovascular adverse event.

See PDR, USPDI or US Hospital Formulary Service for all-inclusive list of side effects.

By my signature below, I GIVE consent for the named medication on Page 1 and anticipated dosage range. My signature also indicates that I understand the following:

- 1. I can refuse to give consent or can withdraw my consent at any time with written notification to the institution director or designee. This will not affect my right to change my decision at a later date. If I withdraw consent after a medication is started, I realize that the medication may not be discontinued immediately. Rather it will be tapered as rapidly as medically safe and then discontinued so as to prevent an adverse medical consequence, such as seizures, due to rapid medication withdrawal.
- 2. Questions regarding this medication can be discussed with the Interdisciplinary Team, including the physician. The staff contact person can assist in making any necessary arrangements.
- 3. Questions regarding any behavior support plan or behavior intervention plan, which correspond with the use of the medication, can be directed to the client's social worker, case manager or psychologist.
- 4. I have the right to request a review at any time of my record, pursuant to ss. 51.30(4)(d) or 51.30(5)(b).
- 5. I have a legal right to file a complaint if I feel that client rights have been inappropriately restricted. The client's social worker, case manager or agency / facility client rights specialist may be contacted for assistance.
- 6. My consent permits the dose to be changed within the anticipated dosage range without signing another consent.
- 7. I understand the reasons for the use of the medication, its potential risks and benefits, other alternative treatment(s) and the probable consequences, which may occur if the proposed medication is not given. I have been given adequate time to study the information and find the information to be specific, accurate and complete.
- 8. This medication consent is for a period effective immediately and not to exceed fifteen (15) months from the date of my signature. The need for and continued use of this medication will be reviewed at least quarterly by the Interdisciplinary Team. The goal, on behalf of the client, will be to arrive at and maintain the client at the minimum effective dose.

Client Initial	Date	

Medication : Adderall;

Adderall XR - (Mixed Salts of A Single Entity Amphetamine)

SIGNATURES	-	DATE SIGNED						
Client – If Presumed Competent to Consent/Parent of Minor/Guardian (POA-HC)	Relationship to Client Self Parent Guardian (POA-HC)							
Staff Present at Oral Discussion	Title							
Client / Parent of Minor / Guardian (POA-HC) Comments								
As parent/guardian (POA-HC) was not available for signature, he/she was verbally informed of the information in this consent.								
Verbal Consent								
Obtained by – PRINT – Staff Name	Date Obtained	Written Consent Received						
Obtained from – PRINT – Parent / Guardian (POA-HC) Name	Date Expires	Date Received						
	Client Initial	Date						